A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Enasidenib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms GFM-IDEAL-Study
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.
- 05 Jan 2019 Planned End Date changed from 12 Nov 2023 to 12 Jan 2023.
- 05 Jan 2019 Planned primary completion date changed from 12 Nov 2021 to 12 Jan 2021.